Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B.
- Author:
Yu-lin ZHOU
1
;
Xue-cai WANG
;
Yin-tao WU
;
Yong-fei TAN
;
Yan-ping ZHAO
;
Jun-ming TANG
;
Jian-qiang PAN
Author Information
- Publication Type:Clinical Trial
- MeSH: Adenine; administration & dosage; analogs & derivatives; Adult; Antiviral Agents; administration & dosage; Drug Administration Schedule; Female; Hepatitis B, Chronic; drug therapy; immunology; Humans; Male; Middle Aged; Organophosphonates; administration & dosage; T-Lymphocytes, Cytotoxic; drug effects; immunology; Young Adult
- From: Chinese Journal of Experimental and Clinical Virology 2010;24(5):362-363
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B (CHB).
METHODS10 mg adefovir dipivoxil (Zhengda Tianjing Pharmaceutical Company) was used for CHB patients with positive HBV DNA (HBV DNA > or = 1 x 10(4) copies/ml), ALT > 2 x upper limit of normal value (ULN) and positive human leucocyte antigen (HLA)-A2, orally, once a day for 3 months. Real time fluorescent quantitative PCR was used to determine HBV DNA and flowcytometer was used to determine HBV specific CTL.
RESULTSAfter treatment with adefovir dipivoxil for 3 months, HBV specific CTL (0.52 +/- 0.11)% was higher than that before treatment (0.34 +/- 0.14)%, t = 6.78 P < 0.01, HBV DNA of 28 cases turned to negative (<1 x 10(3) copies/ml) (62.22%). HBV DNA of 17 cases failed to turn negative 3 months after treatment, but their HBV DNA level was lower [(4. 18 +/- 0.4) log 10 copies/ml] than that before treatment [(6.23 +/- 0.73) log 10 copies/ml], t = 9.99, P < 0.01.
CONCLUSIONAdefovir dipivoxil can improve HBV specific cellular immunity in patients CHB.
